Jinshi data, December 27 news, Haier Biology announced that the company is planning to absorb Shanghai Laisi through Haier Biology to all shareholders of Shanghai Laisi by issuing A shares and raising supporting funds by issuing A shares. Due to the planned major asset restructuring, the company's securities have been suspended from trading since the opening of the market on December 23, 2024, and the suspension is expected to last no more than 10 trading days. As of the date of this announcement, the company and related parties are actively advancing the relevant work of this transaction.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Haier Biomedical: Planning Major Asset Restructuring
Jinshi data, December 27 news, Haier Biology announced that the company is planning to absorb Shanghai Laisi through Haier Biology to all shareholders of Shanghai Laisi by issuing A shares and raising supporting funds by issuing A shares. Due to the planned major asset restructuring, the company's securities have been suspended from trading since the opening of the market on December 23, 2024, and the suspension is expected to last no more than 10 trading days. As of the date of this announcement, the company and related parties are actively advancing the relevant work of this transaction.